LU92710I2 - Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) - Google Patents
Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) Download PDFInfo
- Publication number
- LU92710I2 LU92710I2 LU92710C LU92710C LU92710I2 LU 92710 I2 LU92710 I2 LU 92710I2 LU 92710 C LU92710 C LU 92710C LU 92710 C LU92710 C LU 92710C LU 92710 I2 LU92710 I2 LU 92710I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- antibodies
- cyramza
- ramucirumab
- pharmaceutically acceptable
- acceptable derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36178302P | 2002-03-04 | 2002-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92710I2 true LU92710I2 (fr) | 2015-11-02 |
Family
ID=27805075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92710C LU92710I2 (fr) | 2002-03-04 | 2015-05-06 | Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) |
Country Status (18)
Country | Link |
---|---|
US (2) | US7498414B2 (de) |
EP (3) | EP1487856B1 (de) |
JP (3) | JP2005526506A (de) |
AT (2) | ATE510561T1 (de) |
AU (1) | AU2003213687A1 (de) |
BE (1) | BE2015C027I2 (de) |
CA (1) | CA2478169C (de) |
CY (3) | CY1111141T1 (de) |
DE (1) | DE60333554D1 (de) |
DK (2) | DK1487856T3 (de) |
ES (2) | ES2347543T3 (de) |
FR (1) | FR15C0034I2 (de) |
HK (1) | HK1118229A1 (de) |
HU (1) | HUS1500025I1 (de) |
LU (1) | LU92710I2 (de) |
PT (2) | PT1487856E (de) |
SI (2) | SI1487856T1 (de) |
WO (1) | WO2003075840A2 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
EP1622942B1 (de) | 2003-05-01 | 2014-11-19 | ImClone LLC | Komplett menschliche antikörper gegen den rezeptor des insulin-ähnlichen wachstumsfaktor i |
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20050191293A1 (en) * | 2003-12-10 | 2005-09-01 | Shrikant Deshpande | IP-10 antibodies and their uses |
EP1766093B1 (de) * | 2004-02-06 | 2011-06-15 | University of Massachusetts | Antikörper gegen clostridium difficile-toxine und ihre verwendung |
JP4734319B2 (ja) | 2004-03-19 | 2011-07-27 | イムクローン・リミテッド・ライアビリティ・カンパニー | ヒト抗上皮成長因子受容体抗体 |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
CN101098891B (zh) | 2005-01-05 | 2014-05-21 | F-星生物技术研究与开发有限公司 | 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域 |
US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
US8128929B2 (en) | 2005-06-17 | 2012-03-06 | Imclone Llc | Antibodies against PDGFRa |
US20090197794A1 (en) * | 2005-07-13 | 2009-08-06 | Aird William C | Methods of Diagnosing and Treating an Inflammatory Response |
WO2007068895A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
BRPI0719597A2 (pt) | 2006-11-22 | 2013-12-17 | Adnexus A Bristol Myers Squibb R & D Company | Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir |
WO2008142165A1 (en) * | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
KR100883430B1 (ko) * | 2007-06-13 | 2009-02-12 | 한국생명공학연구원 | 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도 |
US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
CA2691940C (en) * | 2007-07-03 | 2018-03-06 | Joost Alexander Kolkman | Methods for providing improved immunoglobulin sequences |
AU2008278803A1 (en) * | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binging agents directed to KDR and uses thereof - 035 |
UY31478A1 (es) | 2007-11-21 | 2009-07-17 | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
EP2113255A1 (de) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Zytotoxisches Immunglobulin |
JP2011520961A (ja) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
WO2011005377A2 (en) * | 2009-05-27 | 2011-01-13 | Mount Sinai School Of Medicine Of New York University | Compositions and methods comprising vegfr-2 and vegfr-3 antagonists for the treatment of metastatic disease |
US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
KR20120115348A (ko) * | 2009-12-29 | 2012-10-17 | 예일 유니버시티 | 혈관 내피 성장 인자 (vegf) 수용체의 억제제 및 그의 사용 방법 |
WO2011106697A1 (en) | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
EP2600901B1 (de) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US8628773B2 (en) | 2011-04-07 | 2014-01-14 | Amgen Inc. | Antigen binding proteins |
BR112013030352B1 (pt) | 2011-06-02 | 2020-05-19 | Dyax Corp | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
TWI571473B (zh) | 2011-11-02 | 2017-02-21 | 埃派斯進有限公司 | 抗kdr抗體及使用方法 |
EP2791160B1 (de) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modifizierte mrna zusammensetzungen |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
CA2926386C (en) * | 2012-10-05 | 2021-11-09 | Kadmon Corporation, Llc | Human anti-vegfr-2/kdr antibodies |
AU2013348570B2 (en) | 2012-11-21 | 2017-01-12 | Pharmabcine Inc. | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition comprising same |
EP4074834A1 (de) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Am kettenende modifizierte rna |
BR112015009004A8 (pt) | 2012-12-21 | 2021-07-20 | Eisai R&D Man Co Ltd | forma amorfa de derivado de quinolina e método de produção da mesma |
ES2774964T3 (es) | 2013-02-04 | 2020-07-23 | Vascular Biogenics Ltd | Métodos para inducir la capacidad de respuesta a un agente antiangiogénico |
CA2901226C (en) | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Vascular endothelial growth factor binding proteins |
US9618523B2 (en) * | 2013-02-28 | 2017-04-11 | Siemens Healthcare Diagnostics Inc. | Methods and reagents for determining isomeric analytes |
KR20150143458A (ko) | 2013-03-06 | 2015-12-23 | 메리맥 파마슈티컬즈, 인크. | 항-C-MET 탠덤 Fc 이중특이적 항체 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
MX368099B (es) | 2013-05-14 | 2019-09-19 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
KR102127408B1 (ko) * | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
TWI558399B (zh) * | 2014-02-26 | 2016-11-21 | 美國禮來大藥廠 | 癌症之組合療法 |
TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
RU2695332C2 (ru) | 2014-05-15 | 2019-07-23 | Бристол-Маерс Сквибб Компани | Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства |
TWI569808B (zh) | 2014-08-15 | 2017-02-11 | 禮來大藥廠 | 肝細胞腫瘤(hcc)之治療 |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
EP3204423A4 (de) * | 2014-10-07 | 2018-03-28 | Kadmon Corporation, LLC | Menschliche anti-vegfr-2-/kdr-antikörper |
TW201625304A (zh) | 2014-10-24 | 2016-07-16 | 美國禮來大藥廠 | 泌尿上皮癌之療法 |
TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Erk抑制劑 |
CN107427505A (zh) | 2015-02-25 | 2017-12-01 | 卫材R&D管理有限公司 | 用于抑制喹啉衍生物的苦味的方法 |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
HUE053966T2 (hu) | 2015-07-14 | 2021-08-30 | Bristol Myers Squibb Co | Eljárás rák kezelésére immunellenõrzõpont inhibitorral, antitest, amely köt programozott halál-1 receptorhoz (PD-1) vagy programozott halál ligandum 1-hez (PD-L1) |
TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Her3抗體 |
KR101896882B1 (ko) | 2015-11-30 | 2018-09-11 | 앱클론(주) | Vegfr2에 특이적으로 결합하는 항체 |
US20170233480A1 (en) * | 2015-12-31 | 2017-08-17 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
US20190125864A1 (en) | 2016-04-15 | 2019-05-02 | Eli Lilly And Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
CN109069632A (zh) * | 2016-04-15 | 2018-12-21 | 伊莱利利公司 | 用于治疗结直肠癌的雷莫芦单抗和merestinib的组合 |
MX2018013868A (es) | 2016-05-20 | 2019-02-21 | Biohaven Pharm Holding Co Ltd | Uso de agentes de modulacion de glutamato con inmunoterapias para tratar cancer. |
EP3463456A1 (de) | 2016-06-03 | 2019-04-10 | ImClone LLC | Kombination von ramucirumab und pembrolizumab zur behandlung von bestimmten krebsarten |
WO2018069871A2 (en) * | 2016-10-13 | 2018-04-19 | Sorrento Therapeutics, Inc. | Anti-kras binding proteins |
JP2019534888A (ja) | 2016-10-28 | 2019-12-05 | イムクローン・リミテッド・ライアビリティ・カンパニーImclone LLC | 癌の治療のための抗vegfr−2抗体と抗pd−l1抗体との組み合わせ |
MX2019005772A (es) * | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. |
CN106674349B (zh) * | 2017-03-07 | 2018-03-13 | 北京东方百泰生物科技有限公司 | 一种改进的抗vegfr‑2单克隆抗体 |
EP3672633A1 (de) | 2017-08-21 | 2020-07-01 | Eli Lilly and Company | Kombinationen von egfr-inhibitoren und anti-humanen vegfr-2-antikörpern |
US20210322574A1 (en) | 2017-10-20 | 2021-10-21 | Vascular Biogenics Ltd. | Diagnostic methods for anti-angiogenic agent therapy |
BR112020026862A2 (pt) | 2018-06-29 | 2021-04-20 | Gensun Biopharma, Inc. | antagonistas antitumorais de reguladores de pontos de verificação imunológica |
WO2020106886A1 (en) | 2018-11-20 | 2020-05-28 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
AU2020234098A1 (en) | 2019-03-13 | 2021-09-16 | Vascular Biogenics Ltd. | Methods of anti-tumor therapy |
EP3990116A1 (de) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | Antitumor-antagonist bestehend aus einer mutierten tgfss1-rii-extrazellulären domäne und einem immunoglobulin-gerüst |
US20220296926A1 (en) | 2019-07-31 | 2022-09-22 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
MX2022004311A (es) | 2019-10-15 | 2022-05-10 | Lilly Co Eli | Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante. |
CN111024949A (zh) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | 一种重组抗vegfr2单克隆抗体的生物活性分析方法及其应用 |
JP2023540490A (ja) | 2020-09-02 | 2023-09-25 | ファーマブシン インコーポレイテッド | がん患者を治療するためのpd-1拮抗薬及びvegfr-2拮抗薬の併用療法 |
CN114316064A (zh) * | 2020-10-10 | 2022-04-12 | 广东菲鹏制药股份有限公司 | 融合蛋白及其应用 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
US20220389120A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328695A (en) | 1983-03-22 | 1994-07-12 | Massachusetts Institute Of Technology | Muscle morphogenic protein and use thereof |
US5130144B1 (en) | 1984-02-06 | 1995-08-15 | Univ Johns Hopkins | Human stem cells and monoclonal antibodies |
US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
US4683295A (en) | 1984-05-24 | 1987-07-28 | Scripps Clinic And Research Foundation | Method for the preparation of anti-receptor antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5674722A (en) | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE4103975A1 (de) | 1991-02-09 | 1992-08-13 | Thomson Brandt Gmbh | Verfahren zur verkuerzung der zugriffszeit |
CZ282603B6 (cs) | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US20010021382A1 (en) | 1991-03-29 | 2001-09-13 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US5543503A (en) | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
US5367057A (en) | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
ATE239506T1 (de) | 1992-03-05 | 2003-05-15 | Univ Texas | Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren |
US5928947A (en) | 1992-07-27 | 1999-07-27 | California Institute Of Technology | Mammalian multipotent neural stem cells |
US5981569A (en) | 1992-11-13 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
JP3670302B2 (ja) | 1993-07-23 | 2005-07-13 | ファナック株式会社 | 射出成形機における可塑化の管理方法 |
US5599703A (en) | 1993-10-28 | 1997-02-04 | The United States Of America As Represented By The Secretary Of The Navy | In vitro amplification/expansion of CD34+ stem and progenitor cells |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
WO1999014234A2 (en) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
AT402796B (de) | 1995-02-01 | 1997-08-25 | Fritschi Apparatebau | Schibindung |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
JP3658471B2 (ja) | 1996-09-30 | 2005-06-08 | 株式会社日立製作所 | 電子ショッピングシステムにおける買物かご機能の提示方法及び電子ショッピングシステム |
ATE331806T1 (de) | 1996-11-21 | 2006-07-15 | Kyowa Hakko Kogyo Kk | Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
WO1998058053A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Human receptor tyrosine kinase, kdr |
CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
US20020172678A1 (en) * | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
US20030191055A1 (en) | 1999-01-15 | 2003-10-09 | Epstein Stephen E. | Inhibiting development of microvessels withins coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy |
CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
US6245759B1 (en) | 1999-03-11 | 2001-06-12 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6297238B1 (en) | 1999-04-06 | 2001-10-02 | Basf Aktiengesellschaft | Therapeutic agents |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
WO2001074296A2 (en) | 2000-03-31 | 2001-10-11 | Imclone Systems Incorporated | Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
US20020103345A1 (en) | 2000-05-24 | 2002-08-01 | Zhenping Zhu | Bispecific immunoglobulin-like antigen binding proteins and method of production |
CA2450954A1 (en) | 2001-06-20 | 2003-01-03 | Imclone Systems Incorporated | Method of treating atherosclerosis and other inflammatory diseases |
JP2005518336A (ja) | 2001-06-26 | 2005-06-23 | イムクローン システムズ インコーポレイティド | Vegf受容体に結合する二重特異性抗体 |
US6519852B1 (en) | 2001-07-26 | 2003-02-18 | Yuecom Manufacturing Co., Ltd. | Method of manufacturing an aluminum alloy wheel rim |
CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US6844779B2 (en) | 2003-06-19 | 2005-01-18 | The United States Of America As Represented By The Secretary Of The Air Force | Optically isolated bias control circuit |
-
2003
- 2003-03-04 CA CA2478169A patent/CA2478169C/en not_active Expired - Lifetime
- 2003-03-04 WO PCT/US2003/006459 patent/WO2003075840A2/en active Application Filing
- 2003-03-04 EP EP03711375A patent/EP1487856B1/de not_active Expired - Lifetime
- 2003-03-04 DK DK03711375.0T patent/DK1487856T3/da active
- 2003-03-04 PT PT03711375T patent/PT1487856E/pt unknown
- 2003-03-04 ES ES03711375T patent/ES2347543T3/es not_active Expired - Lifetime
- 2003-03-04 AT AT07023361T patent/ATE510561T1/de active
- 2003-03-04 DK DK07023361.4T patent/DK1916001T3/da active
- 2003-03-04 PT PT07023361T patent/PT1916001E/pt unknown
- 2003-03-04 SI SI200331888T patent/SI1487856T1/sl unknown
- 2003-03-04 JP JP2003574116A patent/JP2005526506A/ja active Pending
- 2003-03-04 EP EP07023361A patent/EP1916001B1/de not_active Expired - Lifetime
- 2003-03-04 EP EP10183791A patent/EP2298346A3/de not_active Withdrawn
- 2003-03-04 DE DE60333554T patent/DE60333554D1/de not_active Expired - Lifetime
- 2003-03-04 AT AT03711375T patent/ATE475431T1/de active
- 2003-03-04 US US10/506,997 patent/US7498414B2/en active Active
- 2003-03-04 ES ES07023361T patent/ES2362931T3/es not_active Expired - Lifetime
- 2003-03-04 AU AU2003213687A patent/AU2003213687A1/en not_active Abandoned
- 2003-03-04 SI SI200332035T patent/SI1916001T1/sl unknown
-
2008
- 2008-09-19 US US12/234,203 patent/US8057791B2/en not_active Expired - Lifetime
- 2008-10-30 HK HK08111919.7A patent/HK1118229A1/xx not_active IP Right Cessation
-
2009
- 2009-03-26 JP JP2009076394A patent/JP4970483B2/ja not_active Expired - Lifetime
-
2010
- 2010-08-30 CY CY20101100793T patent/CY1111141T1/el unknown
-
2011
- 2011-06-29 CY CY20111100630T patent/CY1111629T1/el unknown
-
2012
- 2012-02-23 JP JP2012036968A patent/JP5476404B2/ja not_active Expired - Lifetime
-
2015
- 2015-04-28 HU HUS1500025C patent/HUS1500025I1/hu unknown
- 2015-04-30 CY CY2015018C patent/CY2015018I1/el unknown
- 2015-05-06 FR FR15C0034C patent/FR15C0034I2/fr active Active
- 2015-05-06 LU LU92710C patent/LU92710I2/xx unknown
- 2015-05-06 BE BE2015C027C patent/BE2015C027I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92710I2 (fr) | Ramucirumab et ses dérivés pharmaceutiquement acceptables (cyramza) | |
CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
CY1117617T1 (el) | Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας | |
CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CY1116167T1 (el) | Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1 | |
DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
CY1113037T1 (el) | Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα | |
RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
CY1113190T1 (el) | Μεθοδος αγωγης της αιμολυτικης νοσου | |
BR0315161A (pt) | Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição | |
ATE461220T1 (de) | Anti-egfr-antikörper | |
NO20064866L (no) | IRTA-5 antistoffer og deres anvendelse | |
ATE395082T1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
CY1117275T1 (el) | Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους | |
CY1115979T1 (el) | Αντισωματα κατα της μυοστατινης |